Ben Holland Novo Nordisk stands as a titan in the global pharmaceutical landscape, renowned for its pioneering work in diabetes care, obesity treatments, and rare diseases. With blockbuster drugs like Ozempic and Wegovy propelling its market capitalization to over $500 billion as of late 2025, understanding who owns Novo Nordisk is crucial for investors, healthcare professionals, and stakeholders tracking the biotech sector. This article delves into the ownership structure of Novo Nordisk, exploring its historical roots, current shareholder composition, and the influential role of its foundational entities. By examining major shareholders and governance mechanisms, we uncover how this Danish powerhouse maintains stability amid rapid growth in the diabetes and weight-loss markets.
Who Owns WGN America (NewsNation)?
The Historical Foundations of Novo Nordisk’s Ownership
Novo Nordisk’s ownership story is deeply intertwined with Denmark’s innovative spirit and a commitment to scientific philanthropy. The company traces its origins to 1923, when August Krogh, a Nobel Prize-winning physiologist, and his wife Hagedorn founded Novo Terapeutisk Laboratorium in Copenhagen. Their mission was to produce insulin, a breakthrough discovery just two years prior, making it accessible to diabetes patients worldwide. This early venture laid the groundwork for what would become a family-controlled enterprise, but by the 1970s, the need for sustainable funding and broader impact led to the establishment of the Novo Nordisk Foundation in 1980.
The Foundation emerged as a pivotal player, transforming Novo Nordisk from a private laboratory into a publicly traded entity while retaining significant control. In 1989, the merger of Novo Industri and Nordisk Gentofte created Novo Nordisk A/S, marking a new era of global expansion. The Foundation’s foresight ensured that profits were reinvested into research and societal benefits, rather than short-term gains. This structure has shielded the company from hostile takeovers and aligned ownership with long-term innovation—a rarity in the volatile pharma industry.
Today, this historical blueprint continues to define Novo Nordisk’s ownership. The company’s shares are divided into two classes: A shares and B shares. The A shares, which carry 1,000 times the voting power of B shares, are unlisted and exclusively held by Novo Holdings A/S, a wholly owned subsidiary of the Novo Nordisk Foundation. This dual-class system grants the Foundation de facto control, with approximately 77% of voting rights, even as B shares dominate public trading. Such arrangements are common among family- or foundation-led firms like Novo Nordisk, ensuring mission-driven decisions over market whims.
Decoding the Current Ownership Structure
As of November 2025, Novo Nordisk’s ownership reflects a blend of institutional dominance, public dispersion, and foundational oversight. The company is listed on the Nasdaq Copenhagen under the ticker NOVO-B and on the New York Stock Exchange as NVO, making its B shares accessible to a global investor base. However, the Foundation’s grip via Novo Holdings underscores that true power resides in Copenhagen.
Novo Holdings A/S remains the single largest shareholder, controlling 28.19% of the B shares—equivalent to about 1.25 billion shares—valued at billions in market terms. This stake, combined with 100% ownership of the A shares, positions Novo Holdings as the anchor of stability. The entity not only votes on strategic matters but also channels dividends back to the Foundation for reinvestment in life sciences ventures, from startups to academic grants.
Beyond the Foundation’s arm, institutional investors hold the lion’s share of the remaining B shares, totaling around 70-75% of outstanding stock. Retail and individual investors account for roughly 25%, highlighting broad public participation. This distribution fosters liquidity and valuation growth, with Novo Nordisk’s stock surging over 50% year-to-date in 2025, driven by demand for GLP-1 agonists like semaglutide.
Key to this structure is the Novo Nordisk Foundation’s overarching role. As a self-governing Danish institution, it owns Novo Holdings outright and uses it to manage a diversified portfolio exceeding €100 billion in assets. The Foundation’s mandate emphasizes advancing biomedical research and welfare, ensuring that Novo Nordisk’s profits fuel initiatives like the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen. This setup has drawn praise for its ethical alignment but occasional scrutiny for limiting shareholder activism.
Major Shareholders: A Spotlight on Institutional Powerhouses
While Novo Holdings commands the narrative, the roster of top institutional holders reveals a who’s who of global finance influencing Novo Nordisk’s trajectory. BlackRock, Inc., the world’s largest asset manager, tops the list with a 4.10% stake, holding approximately 182 million B shares as of June 2025. BlackRock’s involvement signals confidence in Novo Nordisk’s pipeline, particularly amid expansions into cardiovascular and Alzheimer’s therapies.
Close behind is The Vanguard Group, Inc., with 3.2% ownership through 142 million shares. Vanguard’s passive indexing strategy amplifies its voice in ESG (Environmental, Social, and Governance) voting, pushing Novo Nordisk toward sustainable manufacturing and supply chain transparency—critical as semaglutide shortages gripped headlines in 2024-2025.
Norges Bank Investment Management, Norway’s sovereign wealth fund, holds about 2.5%, while State Street Global Advisors and Capital Research Global Investors each command around 2-3%. These U.S.- and Europe-based giants collectively wield influence on board elections and executive compensation, though the A shares’ voting supremacy tempers their sway.
Insider ownership remains modest at under 0.1%, typical for a mature pharma giant. CEO Lars Fruergaard Jørgensen and other executives hold minimal direct stakes, emphasizing alignment through performance incentives rather than equity concentration. This low insider figure contrasts with tech firms but aligns with Novo Nordisk’s foundation-centric model, where loyalty stems from mission over money.
Recent filings show minor fluctuations: For instance, Morgan Stanley increased its position to 14.28 million shares in Q2 2025, betting on obesity market dominance. No seismic shifts have occurred, but the 2025 board overhaul—triggered by Foundation-led disagreements over leadership—hints at subtle ownership tensions manifesting in governance. An Extraordinary General Meeting on November 14, 2025, installed a new board under former CEO Lars Rebien Sørensen, reinforcing the Foundation’s veto power without altering shareholdings.
Governance and the Foundation’s Enduring Influence
Novo Nordisk’s corporate governance is a masterclass in balanced control. The Board of Directors, comprising 10 members as of late 2025, includes Foundation nominees and independents, ensuring diverse expertise in pharma, finance, and ethics. Chair Jeppe Christiansen, a Foundation representative, oversees strategy, while committees on audit, remuneration, and scientific affairs maintain transparency.
The Foundation’s influence extends beyond voting blocs. Through Novo Holdings, it incubates spin-offs like NovoCure and invests in over 100 life sciences firms, creating a virtuous cycle of innovation. This ecosystem has propelled Novo Nordisk’s R&D spend to €4 billion annually, funding trials for next-gen insulins and gene therapies.
Critics occasionally question the dual-class model’s dilution of minority voices, but proponents argue it safeguards against quarterly pressures, enabling bold moves like the $16.5 billion Catalent acquisition in 2024 to bolster Wegovy production. In a sector plagued by patent cliffs and regulatory hurdles, this ownership fortifies resilience.
Implications for Investors and the Future Horizon
For investors eyeing Novo Nordisk stock ownership, the structure offers stability with growth upside. The Foundation’s long-term horizon mitigates volatility, as evidenced by a 15-year compound annual growth rate exceeding 20%. Yet, with GLP-1 patents nearing expiration in the 2030s, diversification into hemophilia and growth hormone therapies will test shareholder unity.
Looking ahead, no major ownership changes are anticipated in 2025, per recent disclosures. The board refresh signals proactive adaptation, potentially unlocking value in emerging markets like Asia, where diabetes prevalence surges.
In summary, Novo Nordisk’s ownership is a testament to visionary stewardship. Dominated by the Novo Nordisk Foundation via Novo Holdings, augmented by elite institutions like BlackRock and Vanguard, it exemplifies how ethical foundations can coexist with capitalist dynamism. As the company navigates a transformative era in metabolic health, its shareholder base remains a bedrock for sustained impact.
References
- Novo Nordisk. (2025). Share and ownership structure of Novo Nordisk. Retrieved from https://www.novonordisk.com/investors/stock-information/share-and-ownership-structure.html
- Investing.com. (2025). Who Owns Novo Nordisk B? NOVOb Shareholders. Retrieved from https://www.investing.com/equities/novo-nordisk-ownership
- Novo Nordisk Fonden. (2024). Ownership. Retrieved from https://novonordiskfonden.dk/en/who-we-are/ownership/
- TipRanks.com. (2025). Who owns Novo Nordisk? NVO Stock Ownership. Retrieved from https://www.tipranks.com/stocks/nvo/ownership
- Simply Wall St. (2025). Novo Nordisk Ownership – Insider Trading Volume. Retrieved from https://simplywall.st/stocks/us/pharmaceuticals-biotech/otc-nono.f/novo-nordisk/ownership
- Yahoo Finance. (2025). Novo Nordisk A/S (NVO) Stock Major Holders. Retrieved from https://finance.yahoo.com/quote/NVO/holders/
